Summary:
- Researchers have developed "masked antibodies" that remain inactive until they reach the specific intracellular environment of neurons, potentially overcoming the challenge of delivering therapeutic proteins across the blood-brain barrier and cell membranes.
- This innovative approach aims to target intracellular alpha-synuclein aggregates, a hallmark of Parkinson’s disease, which were previously considered "undruggable" by conventional antibody therapies.
- The study represents a significant advancement in neuropharmacology, offering a potential pathway for treating neurodegenerative disorders by enabling precise, site-specific protein-based interventions.